Clinical trial
Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer…
NCT00087269 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00087269 |
|---|---|
| Title | Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection |
| Official title | Phase II Study to Evaluate the Tumor Biochemical Effects of the EGFR Tyrosine Kinase Inhibitor OSI-774 (Erlotinib) Administered Prior to Surgical Resection in Patients With Early Stage Non-Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer |
| Intervention type | Drug, Other, Procedure |
| Interventions | erlotinib hydrochloride, therapeutic endoscopic surgery, laboratory biomarker analysis |
| Enrollment | 110 |
| Start date | Dec 1, 2004 |
| Primary completion | Apr 1, 2006 |
| First posted | Jul 12, 2004 |
| Last update posted | Jun 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: